{'fraction_non_alphanumeric': 0.026600985221674877, 'fraction_numerical': 0.0009852216748768472, 'mean_word_length': 5.554838709677419, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Quality of life in patients with multiple myeloma

Dear Editor, Multiple myeloma (MM) is a common hematological malignancy in India. With the advent of novel therapies and increased use of high‐dose chemotherapy with autologous stem cell transplant, the survival of patients with myeloma has significantly improved.[1] The aims of MM treatment are to control disease, prolong survival, and maximize patient well‐being. Despite the considerable improvements in the treatment, many MM patients will experience multiple subsequent relapses of their disease requiring subsequent treatment. While MM has no cure, successive lines of treatment can lead to a greater risk of developing adverse reactions that could be, in turn, responsible for the sequelae and create handicaps impacting patients’ quality of life. Health‐related quality‐of‐life (HRQoL) instruments can be incorporated into clinical studies to get a more comprehensive evaluation of treatment outcomes. The data on HRQoL in the Indian scenario are sparse.